BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 30027756)

  • 1. Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just for Pain.
    Zhi WI; Ingram E; Li SQ; Chen P; Piulson L; Bao T
    Integr Cancer Ther; 2018 Dec; 17(4):1079-1086. PubMed ID: 30027756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
    Bao T; Goloubeva O; Pelser C; Porter N; Primrose J; Hester L; Sadowska M; Lapidus R; Medeiros M; Lao L; Dorsey SG; Badros AZ
    Integr Cancer Ther; 2014 Sep; 13(5):396-404. PubMed ID: 24867959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction.
    Lakshman A; Modi M; Prakash G; Malhotra P; Khadwal A; Jain S; Kumari S; Varma N; Varma S
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):513-519.e1. PubMed ID: 28842138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
    Bao T; Seidman AD; Piulson L; Vertosick E; Chen X; Vickers AJ; Blinder VS; Zhi WI; Li Q; Vahdat LT; Dickler MN; Robson ME; Mao JJ
    Eur J Cancer; 2018 Sep; 101():12-19. PubMed ID: 30007894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.
    Garcia MK; Cohen L; Guo Y; Zhou Y; You B; Chiang J; Orlowski RZ; Weber D; Shah J; Alexanian R; Thomas S; Romaguera J; Zhang L; Badillo M; Chen Y; Wei Q; Lee R; Delasalle K; Green V; Wang M
    J Hematol Oncol; 2014 May; 7():41. PubMed ID: 24886772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma.
    Han X; Wang L; Shi H; Zheng G; He J; Wu W; Shi J; Wei G; Zheng W; Sun J; Huang H; Cai Z
    BMC Cancer; 2017 Jan; 17(1):40. PubMed ID: 28068938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
    Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
    J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of Bortezomib-Induced Peripheral Neuropathy in Newly Multiple Myeloma Patients Using Nervonic Acid, Curcuma Rizoma, and L-Arginine Compound: A Pilot Study.
    Maschio M; Maialetti A; Marchesi F; Gumenyuk S; Pisani F; Papa E; Galiè E; Koudriavtseva T; Graziano G; Giannarelli D; Mengarelli A
    Integr Cancer Ther; 2022; 21():15347354221114142. PubMed ID: 35866451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial.
    Bao T; Baser R; Chen C; Weitzman M; Zhang YL; Seluzicki C; Li QS; Piulson L; Zhi WI
    Oncologist; 2021 Nov; 26(11):e2070-e2078. PubMed ID: 34390283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral neuropathy exacerbated by lenalidomide in a patient with multiple myeloma.
    Kamimura T; Miyamoto T; Yokota N; Aoki T; Ito Y; Akashi K
    Intern Med; 2014; 53(15):1651-3. PubMed ID: 25088880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
    Cheng HL; Molassiotis A
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of bortezomib-induced peripheral neuropathy with the R-R interval variation of the electrocardiogram in plasma cell myeloma: a retrospective study.
    Nishiwaki U; Yokote T; Hatooka J; Miyoshi T; Iwaki K; Masuda Y; Fujimoto M; Ueda M; Kinoshita Y; Arita Y; Shimizu M; Yamada T; Tanabe K; Akioka T; Imagawa A
    Leuk Lymphoma; 2020 Mar; 61(3):707-713. PubMed ID: 31642372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.
    Cheng HL; Lopez V; Lam SC; Leung AKT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; De Ng TR; Suen LKP; Chan CW; Yorke J; Molassiotis A
    Health Qual Life Outcomes; 2020 Jul; 18(1):246. PubMed ID: 32703223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment.
    Velasco R; Alberti P; Bruna J; Psimaras D; Argyriou AA
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S52-S62. PubMed ID: 31647153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acupuncture for neuropathic pain due to bortezomib in a patient with multiple myeloma.
    Mandıroğlu S; Cevik C; Aylı M
    Acupunct Med; 2014 Apr; 32(2):194-6. PubMed ID: 24389811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment.
    Zanville NR; Nudelman KN; Smith DJ; Von Ah D; McDonald BC; Champion VL; Saykin AJ
    Support Care Cancer; 2016 Nov; 24(11):4779-89. PubMed ID: 27470258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials.
    Li T; Timmins HC; King T; Kiernan MC; Goldstein D; Park SB
    Hematol Oncol; 2020 Aug; 38(3):229-243. PubMed ID: 31873944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy.
    Yan W; Wu Z; Zhang Y; Hong D; Dong X; Liu L; Rao Y; Huang L; Zhang X; Wu J
    Biomed Pharmacother; 2021 Oct; 142():112068. PubMed ID: 34463262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized Assessor-Blinded Wait-List-Controlled Trial to Assess the Effectiveness of Acupuncture in the Management of Chemotherapy-Induced Peripheral Neuropathy.
    Molassiotis A; Suen LKP; Cheng HL; Mok TSK; Lee SCY; Wang CH; Lee P; Leung H; Chan V; Lau TKH; Yeo W
    Integr Cancer Ther; 2019; 18():1534735419836501. PubMed ID: 30905173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prophylaxis of Bortezomib-Induced Peripheral Neuropathy in Patients with Multiple Myeloma by High-Dose Intravenous Mecobalamin].
    Zhang LL; Wang YH; Shao ZH; Ma J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):480-484. PubMed ID: 28446297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.